Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

An RNA interference (RNAi) therapy uses small pieces of non-coding RNA to block how certain genes are expressed. In 2018, Alnylam Pharmaceuticals’ Onpattro became the first FDA-approved RNAi drug.

RNAi (RNA interference) is a biological process in which RNA molecules—microRNA (miRNA) and small interfering RNA (siRNA)—inhibit gene expression, typically by binding to messenger RNA (mRNA ...

PORTLAND, IN, UNITED STATES, January 28, 2025 /EINPresswire / -- The RNA based therapeutics has been explored as a promising treatment option for the diseases which are difficult to treat. Development ...

H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating and $75 price target on Silence Therapeutics (SLN) shares following a recent ...

"RNA interference is a well-known type of gene regulation in which cells can turn down the expression of a gene by expressing a small RNA that can base pair with the RNA of the target gene. This type ...

Q4 2024 Earnings Call Feb 04, 2025, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants.

The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat ...

Get Instant Summarized Text (Gist) A bacterial pathogen enhances gut colonization by regulating N-acetylneuraminic acid (Neu5Ac) metabolism through a novel small noncoding RNA. This RNA, derived ...